BioMarin Pharmaceutical Inc. (BM8.DE)
EUR 61.96
(-1.71%)
EUR 61.96
(-1.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 276.48 Million USD | 94.14% |
| 2022 | 163.32 Million USD | 232.14% |
| 2021 | 33.72 Million USD | 920.96% |
| 2020 | 35.33 Million USD | 73.7% |
| 2019 | -22.24 Million USD | 77.81% |
| 2018 | -100.25 Million USD | -39.82% |
| 2017 | -71.69 Million USD | 62.74% |
| 2016 | -192.43 Million USD | 33.02% |
| 2015 | -287.27 Million USD | -108.54% |
| 2014 | -137.75 Million USD | -15.97% |
| 2013 | -118.79 Million USD | -29.23% |
| 2012 | -91.92 Million USD | -187.67% |
| 2011 | -31.95 Million USD | -495.91% |
| 2010 | 8.07 Million USD | -63.03% |
| 2009 | 21.83 Million USD | -59.71% |
| 2008 | 54.18 Million USD | 202.4% |
| 2007 | -52.91 Million USD | -316.18% |
| 2006 | -12.71 Million USD | 76.51% |
| 2005 | -54.13 Million USD | -54.99% |
| 2004 | -34.92 Million USD | 26.72% |
| 2003 | -47.66 Million USD | -24.3% |
| 2002 | -38.35 Million USD | -77.13% |
| 2001 | -21.65 Million USD | -18.1% |
| 2000 | -18.33 Million USD | 4.85% |
| 1999 | -19.26 Million USD | -51.72% |
| 1998 | -12.7 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 126.44 Million USD | 144.61% |
| 2023 Q1 | 86.88 Million USD | 718.01% |
| 2023 FY | - USD | 94.14% |
| 2023 Q3 | 71.13 Million USD | -28.86% |
| 2023 Q4 | 51.69 Million USD | -27.33% |
| 2023 Q2 | 99.98 Million USD | 15.08% |
| 2022 Q4 | 10.62 Million USD | -61.49% |
| 2022 Q3 | 27.57 Million USD | -56.9% |
| 2022 Q1 | 57.33 Million USD | 256.05% |
| 2022 Q2 | 63.98 Million USD | 11.59% |
| 2022 FY | - USD | 232.14% |
| 2021 Q3 | -15.45 Million USD | -134.18% |
| 2021 Q4 | -36.74 Million USD | -137.8% |
| 2021 FY | - USD | 920.96% |
| 2021 Q1 | 55.01 Million USD | 427.55% |
| 2021 Q2 | 45.2 Million USD | -17.83% |
| 2020 FY | - USD | 73.7% |
| 2020 Q3 | -34.19 Million USD | -77.03% |
| 2020 Q1 | 64.44 Million USD | 1455.61% |
| 2020 Q2 | -19.31 Million USD | -129.97% |
| 2020 Q4 | -16.79 Million USD | 50.87% |
| 2019 Q2 | -29.74 Million USD | -12.39% |
| 2019 FY | - USD | 77.81% |
| 2019 Q1 | -26.46 Million USD | 54.98% |
| 2019 Q4 | 4.14 Million USD | -86.11% |
| 2019 Q3 | 29.82 Million USD | 200.27% |
| 2018 Q2 | -26.72 Million USD | -2.63% |
| 2018 FY | - USD | -39.82% |
| 2018 Q1 | -26.04 Million USD | 32.12% |
| 2018 Q3 | 11.29 Million USD | 142.28% |
| 2018 Q4 | -58.78 Million USD | -620.3% |
| 2017 Q2 | -17.3 Million USD | -498.87% |
| 2017 Q3 | -5.97 Million USD | 65.46% |
| 2017 FY | - USD | 62.74% |
| 2017 Q1 | 4.33 Million USD | 105.78% |
| 2017 Q4 | -38.36 Million USD | -541.84% |
| 2016 Q4 | -75.06 Million USD | -59.12% |
| 2016 Q2 | 26.11 Million USD | 137.94% |
| 2016 Q1 | -68.84 Million USD | -0.5% |
| 2016 FY | - USD | 33.02% |
| 2016 Q3 | -47.17 Million USD | -280.64% |
| 2015 FY | - USD | -108.54% |
| 2015 Q1 | -63.81 Million USD | -16.9% |
| 2015 Q4 | -68.5 Million USD | 14.05% |
| 2015 Q3 | -79.69 Million USD | -39.64% |
| 2015 Q2 | -57.07 Million USD | 10.56% |
| 2014 Q1 | -16.56 Million USD | 60.94% |
| 2014 Q4 | -54.58 Million USD | -4.51% |
| 2014 FY | - USD | -15.97% |
| 2014 Q3 | -52.22 Million USD | -251.96% |
| 2014 Q2 | -14.83 Million USD | 10.4% |
| 2013 Q2 | -19.68 Million USD | 47.13% |
| 2013 Q1 | -37.24 Million USD | -5.6% |
| 2013 Q3 | -42.15 Million USD | -114.09% |
| 2013 Q4 | -42.39 Million USD | -0.59% |
| 2013 FY | - USD | -29.23% |
| 2012 FY | - USD | -187.67% |
| 2012 Q4 | -35.26 Million USD | -309.78% |
| 2012 Q1 | -19.76 Million USD | -67.35% |
| 2012 Q2 | -28.26 Million USD | -43.01% |
| 2012 Q3 | -8.6 Million USD | 69.56% |
| 2011 Q2 | 899 Thousand USD | -68.41% |
| 2011 Q4 | -11.81 Million USD | 4.46% |
| 2011 FY | - USD | -495.91% |
| 2011 Q3 | -12.36 Million USD | -1475.19% |
| 2011 Q1 | 2.84 Million USD | -39.49% |
| 2010 Q1 | 3.94 Million USD | -65.58% |
| 2010 Q2 | 4.79 Million USD | 21.58% |
| 2010 Q3 | 2.36 Million USD | -50.73% |
| 2010 Q4 | 4.7 Million USD | 99.11% |
| 2010 FY | - USD | -63.03% |
| 2009 Q4 | 11.45 Million USD | 9.0% |
| 2009 Q3 | 10.51 Million USD | 0.28% |
| 2009 FY | - USD | -59.71% |
| 2009 Q1 | 2.3 Million USD | -95.59% |
| 2009 Q2 | 10.48 Million USD | 354.16% |
| 2008 Q2 | 7.53 Million USD | 294.4% |
| 2008 Q4 | 52.34 Million USD | 815.42% |
| 2008 Q3 | 5.71 Million USD | -24.13% |
| 2008 Q1 | 1.91 Million USD | 123.09% |
| 2008 FY | - USD | 202.4% |
| 2007 Q1 | -15.72 Million USD | -74.65% |
| 2007 Q2 | -12.5 Million USD | 20.44% |
| 2007 Q4 | -8.27 Million USD | 49.56% |
| 2007 Q3 | -16.4 Million USD | -31.18% |
| 2007 FY | - USD | -316.18% |
| 2006 Q2 | 2.43 Million USD | 147.61% |
| 2006 Q3 | 2.28 Million USD | -6.31% |
| 2006 FY | - USD | 76.51% |
| 2006 Q4 | -9 Million USD | -493.96% |
| 2006 Q1 | -5.12 Million USD | 49.03% |
| 2005 Q2 | -16.36 Million USD | 25.47% |
| 2005 Q1 | -21.96 Million USD | -23.24% |
| 2005 Q3 | -10.74 Million USD | 34.36% |
| 2005 Q4 | -10.05 Million USD | 6.46% |
| 2005 FY | - USD | -54.99% |
| 2004 Q3 | -20.41 Million USD | -195.99% |
| 2004 Q2 | 21.26 Million USD | 224.48% |
| 2004 Q1 | -17.08 Million USD | 24.83% |
| 2004 FY | - USD | 26.72% |
| 2004 Q4 | -17.82 Million USD | 12.7% |
| 2003 FY | - USD | -24.3% |
| 2003 Q1 | -15.2 Million USD | 30.68% |
| 2003 Q2 | -7.43 Million USD | 51.08% |
| 2003 Q3 | -17.73 Million USD | -138.51% |
| 2003 Q4 | -22.72 Million USD | -28.13% |
| 2002 Q3 | -10.31 Million USD | -23.74% |
| 2002 Q4 | -21.92 Million USD | -112.59% |
| 2002 FY | - USD | -77.13% |
| 2002 Q1 | 2.23 Million USD | 171.36% |
| 2002 Q2 | -8.33 Million USD | -473.81% |
| 2001 Q3 | -5.6 Million USD | 18.4% |
| 2001 Q1 | -6.05 Million USD | 13.1% |
| 2001 Q4 | -3.12 Million USD | 44.26% |
| 2001 Q2 | -6.87 Million USD | -13.55% |
| 2001 FY | - USD | -18.1% |
| 2000 Q4 | -6.96 Million USD | -21.08% |
| 2000 FY | - USD | 4.85% |
| 2000 Q3 | -5.75 Million USD | -19.97% |
| 2000 Q1 | -828 Thousand USD | 86.35% |
| 2000 Q2 | -4.79 Million USD | -478.86% |
| 1999 Q2 | -4.5 Million USD | 76.44% |
| 1999 Q3 | -5.3 Million USD | -17.78% |
| 1999 Q4 | -6.06 Million USD | -14.49% |
| 1999 FY | - USD | -51.72% |
| 1999 Q1 | -19.1 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 74.579% |
| CureVac N.V. | -234.09 Million EUR | 218.11% |
| Biotest Aktiengesellschaft | 179 Million EUR | -54.46% |
| Biotest Aktiengesellschaft | 179 Million EUR | -54.46% |
| BRAIN Biotech AG | -2.38 Million EUR | 11682.866% |
| Formycon AG | 81.05 Million EUR | -241.114% |
| Heidelberg Pharma AG | -18.7 Million EUR | 1578.015% |
| Medigene AG | -14.58 Million EUR | 1995.667% |